The Oncologist Journal focuses on medical and practice issues of busy oncology, hematology and radiation professionals to aid in better cancer patient care.
Durham, NC, USA
Joined July 2010
- Tweets3.2K
- Following316
- Followers25.9K
- Likes736
Pinned Tweet
Submit to our special series on Clinical Cancer Epidemiology & Real-World Evidence to help advance oncology care across prevention, diagnosis, treatment, and survivorship.
👉Learn more and submit your research:
academic.oup.com/oncolo/page…
@susanebates @gbanna74 @PasRescigno
Caregivers are part of the treatment experience. In 122 pts on 2nd-line therapy for metastatic breast cancer, caregiver fatigue & QoL tracked w/ pt distress over 6 mo of ePROM collection. #BreastCancerAwareness
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
📣Oxford University Press invites applications for the position of Deputy Editor for The Oncologist.
Applications are due Saturday, October 31, 2026.
Find the job description and application instructions here: academic.oup.com/oncolo/page…
@susanebates @gbanna74 @PasRescigno
⏰Just one week left to submit to our special series!
Submit by October 31st: academic.oup.com/oncolo/page…
#Oncology #CallForPapers #RealWorldEvidence #CancerResearch
@susanebates @gbanna74 @PasRescigno
Distinct sleep and rest-activity profiles according to adjuvant treatment exposure in women treated for breast cancer
#BreastCancerAwareness #sleep #fatigue
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
Comparative safety of concurrent adjuvant trastuzumab emtansine versus trastuzumab with radiotherapy in HER2-positive early breast cancer
#BreastCancerAwareness #radiotherapy #toxicity
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
A View from the Periphery: Trial Design, Commercial Competition, and the Access Gap in Multiple Myeloma
@susanebates @gbanna74 @PasRescigno @drMehmetbaysal
doi.org/10.1093/oncolo/oyag3…
There’s still time!
The Oncologist is calling for manuscripts to be included in this special series. Submission deadline: Oct 31, 2026.
📑Submit your manuscript today: academic.oup.com/oncolo/page…
@susanebates @gbanna74 @PasRescigno
This small pilot trial suggests #cannabis may improve symptoms in #pancsm w/ ≥10 mg/day #THC 🌿 linked to ⬆️symptom improvement. Higher #THC doses also correlated w/ reduced #anxiety & #insomnia. #PallOnc #SuppOnc
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
International survey highlights that drug–drug interactions remain a major challenge in #ProstateCancer care. #MeetURO #ONCOassist
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
Overall survival in oncology phase III trials: an individual patient level meta-analysis (OPTIMA)
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag1…
📢 REMINDER: only a few weeks left to submit to our special series (submission deadline: 10/31/2026)
👉academic.oup.com/oncolo/page…
#Oncology #CallForPapers #RealWorldEvidence
@susanebates @gbanna74 @PasRescigno
This retrospective analysis showed that #nilotinib provided an effective and well-tolerated alternative after severe #imatinib toxicity, particularly in KIT exon 11–mutant #GIST, but lacked activity against exon 9.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
Real-world #US 🇺🇸 data show #IO + #FOLFOX #CAPOX was the most common first-line therapy and improved #OS vs chemotherapy alone, driven by PD-L1 #CPS ≥1. Outcomes remained poor and more studies are needed.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
A small #Japan 🇯🇵 Ph2 study suggests #goshajinkigan, a native herb, may reduce grade ≥2 paclitaxel neuropathy 🔥⚡️, but results were less certain after stratification. Larger, blinded phase III trials are needed
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
Oxford University Press invites applications for the position of Deputy Editor for The Oncologist.
For more information: academic.oup.com/oncolo/page…
Applications are due October 31st.
@susanebates @gbanna74 @PasRescigno
🧬Combination ICI outcomes in heavily pretreated advanced sarcoma: although many patients had rapid progression, durable responses were seen in carefully selected patients, including those with ultra-rare histologies. @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo/oyag3…
📢 Reminder! The Oncologist Call for Papers
👉Submission Deadline: October 31, 2026
academic.oup.com/oncolo/page…
@susanebates @gbanna74 @PasRescigno
FOLFOXIRI plus panitumumab for left-sided RAS-wild-type metastatic colorectal cancer
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
Recrudescence of a FLT3 wild-type CMML clone after allogeneic stem cell transplant for FLT3-ITD acute myeloid leukemia
#BloodCancerAwareness
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag2…
